Study Results Of Gammagard S D And Gammagard Liquid In Patients With Mild-To-Moderate Alzheimer's Disease Announced
Added: 03 мая 2008
Last relative articles:
- Invest In A Future Without Dementia
- Advance Towards Early Alzheimer's Diagnosis
- Suven Life Sciences Initiates Phase I Clinical Trials In Europe Of SUVN-502 For Alzheimer's Disease
- Elan And Wyeth Announce Encouraging Top-line Results From Phase 2 Clinical Trial Of Bapineuzumab For Alzheimer's Disease
- Molecular Imaging Sheds New Light On Progression Of Alzheimer's Disease
- Known Genetic Risk For Alzheimer's In Whites Also Places Blacks At Risk
- UQ-US Team Targets Faster Alzheimer's Detection
- Researchers Link Memory Loss To Poor Diet
- New Campaign Launched In Wales: Are You Worried About Your Memory?
- The APCs Of Nerve Cell Function
Comments: [0] / Post comment:
05 Jan 2009 16:15:54
Market Report -- In Play () - MSN Money
Market Report -- In Play () MSN Money - Baxter International (BAX) and Halozyme Therapeutics (HALO) announce the start of a Phase III clinical trial of Baxter's GAMMAGARD LIQUID 10%, ...
05 Jan 2009 16:06:25
Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in ... - Reuters
Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in ... Reuters - The purpose of this clinical trial is to evaluate the safety and efficacy and gain regulatory approval for the treatment of PID using GAMMAGARD LIQUID and ... Halozyme Receives $5.5 Million Payment From Baxter